Keywords: gilead, 2nd-qtr, revenues, up, usa-based, biotechnology, company
Gilead's 2nd-qtr revenues up 55%
Article | 01 August 2005
USA-based biotechnology company Gilead Sciences has reported record revenues for the second quarter of 2005, jumping 55% to $495.3 milliona and with HIV/ ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
